Codice QR

Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study

BackgroundLanadelumab is a plasma kallikrein inhibitor approved in many countries, including China, for the long-term prophylaxis of hereditary angioedema (HAE). The primary objective was safety evaluation of lanadelumab for HAE long-term prophylaxis in a Chinese patient population. Secondary object...

Descrizione completa

Salvato in:
Autori principali: Yuxiang Zhi, Rongfei Zhu, Yuemei Sun, He Lai, Hong Ren, Yi Wang, Lin Dong
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2026-04-01
Serie:Frontiers in Immunology
Soggetti:
Chinese patients
HAE long-term prophylaxis
hereditary angioedema
lanadelumab
pharmacodynamics
pharmacokinetics
Accesso online:https://www.frontiersin.org/articles/10.3389/fimmu.2026.1750735/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi